6,467 Shares in CVS Health Co. (NYSE:CVS) Bought by Carson Advisory Inc.

Carson Advisory Inc. acquired a new position in shares of CVS Health Co. (NYSE:CVS - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 6,467 shares of the pharmacy operator's stock, valued at approximately $290,000.

A number of other institutional investors have also recently bought and sold shares of the company. Ridgewood Investments LLC boosted its holdings in CVS Health by 255.7% in the fourth quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock worth $28,000 after purchasing an additional 450 shares in the last quarter. Stonebridge Financial Group LLC acquired a new position in shares of CVS Health during the 4th quarter valued at about $28,000. Hopwood Financial Services Inc. bought a new position in shares of CVS Health in the 4th quarter valued at approximately $29,000. Financial Perspectives Inc lifted its holdings in CVS Health by 137.5% in the 4th quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock worth $36,000 after purchasing an additional 466 shares during the last quarter. Finally, MidAtlantic Capital Management Inc. boosted its position in CVS Health by 112.1% during the fourth quarter. MidAtlantic Capital Management Inc. now owns 827 shares of the pharmacy operator's stock worth $37,000 after purchasing an additional 437 shares during the period. Institutional investors and hedge funds own 80.66% of the company's stock.

Insider Buying and Selling at CVS Health

In other news, SVP James David Clark sold 7,513 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares in the company, valued at $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Michael F. Mahoney purchased 30,000 shares of CVS Health stock in a transaction that occurred on Tuesday, February 18th. The stock was purchased at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the purchase, the director now directly owns 39,356 shares in the company, valued at $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.24% of the company's stock.

CVS Health Stock Down 2.0 %

CVS traded down $1.37 during trading on Friday, reaching $67.19. The company had a trading volume of 16,054,208 shares, compared to its average volume of 11,804,494. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $71.45. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. The business's fifty day moving average price is $66.22 and its 200 day moving average price is $58.76. The company has a market cap of $84.71 billion, a P/E ratio of 18.36, a PEG ratio of 0.98 and a beta of 0.57.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Equities analysts anticipate that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be paid a $0.665 dividend. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 annualized dividend and a yield of 3.96%. CVS Health's dividend payout ratio (DPR) is currently 72.68%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CVS. Morgan Stanley restated an "overweight" rating on shares of CVS Health in a research note on Tuesday. StockNews.com raised CVS Health from a "sell" rating to a "hold" rating in a research report on Thursday, February 13th. Argus set a $77.00 target price on shares of CVS Health in a research note on Tuesday, February 18th. Barclays boosted their price objective on CVS Health from $71.00 to $73.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Finally, Cantor Fitzgerald upgraded shares of CVS Health from a "neutral" rating to an "overweight" rating in a research report on Wednesday, February 12th. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $71.83.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.